Stereotaxis (STXS) Stock Price, News & Analysis

Company Overview

Stereotaxis, Inc. develops and commercializes robotic magnetic navigation systems designed to advance the treatment of cardiac arrhythmias. By harnessing precise magnetic fields, the company’s platforms allow electrophysiologists to navigate specially designed catheters through the vascular system with submillimeter accuracy. This remote navigation technology aims to reduce procedure times, improve safety, and enhance clinical outcomes for patients undergoing complex catheter‐based ablations.

The company’s flagship offerings include the Niobe® and Genesis RMN® (Remote Magnetic Navigation) systems, which integrate seamlessly with existing imaging and mapping equipment in catheterization laboratories. These systems are supported by proprietary software that provides real‐time visualization of catheter position and automated control algorithms to assist in lesion delivery. Ancillary products, such as navigation catheters, patches, and system upgrades, complement its core robotic platforms and support ongoing procedural innovations.

Since its founding in 1996 and headquarters in St. Louis, Missouri, Stereotaxis has expanded its reach to major medical centers across North America, Europe and the Asia‐Pacific region. Collaborative research agreements with leading cardiac institutes have fostered continuous product enhancements and clinical validation studies. The company leverages a global service network to provide installation, training, and technical support, ensuring that clinical teams can fully utilize the unique capabilities of its robotic systems.

Guided by a seasoned management team with deep expertise in medical device development, regulatory affairs, and cardiovascular electrophysiology, Stereotaxis pursues strategic partnerships to broaden its technology applications. The Board of Directors and executive leadership work closely with key opinion leaders in the arrhythmia community to drive adoption, refine system performance, and explore future expansions into adjacent interventional markets.

Key Stats

• Today's Range: $2.26 to $2.40
• 50-Day Range: $2.02 to $2.37
• 52-Week Range: $1.54 to $2.72
• Volume: 329,430 shs
• Average Volume: 336,005 shs
• Market Capitalization: $205.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Stereotaxis Stock Analysis - MarketRank™

Stereotaxis scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Stereotaxis.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Stereotaxis are expected to grow in the coming year, from ($0.26) to ($0.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stereotaxis is -7.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stereotaxis is -7.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Stereotaxis has a P/B Ratio of 33.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.34% of the float of Stereotaxis has been sold short.

Short Interest Ratio / Days to Cover

Stereotaxis has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Stereotaxis has recently increased by 5.93%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Stereotaxis does not currently pay a dividend.

Dividend Growth

Stereotaxis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.34% of the float of Stereotaxis has been sold short.

Short Interest Ratio / Days to Cover

Stereotaxis has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Stereotaxis has recently increased by 5.93%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.74

News Sentiment

Stereotaxis has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Stereotaxis this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Stereotaxis insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.77% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STXS Stock Analysis - Frequently Asked Questions

How have STXS shares performed this year?

Stereotaxis' stock was trading at $2.29 at the beginning of the year. Since then, STXS shares have increased by 3.7% and is now trading at $2.3750.

How were Stereotaxis' earnings last quarter?

Stereotaxis Inc. (NYSEAMERICAN:STXS) announced its earnings results on Monday, November, 11th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.03. The business had revenue of $9.20 million for the quarter, compared to analyst estimates of $6.80 million. Stereotaxis had a negative net margin of 92.19% and a negative trailing twelve-month return on equity of 325.86%.
Read the conference call transcript.

How do I buy shares of Stereotaxis?

Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Stereotaxis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stereotaxis investors own include Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/11/2024
• Today: 7/16/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:STXS
• CIK: 1289340
• Web: www.stereotaxis.com
• Phone: (314) 678-6100
• Fax: 314-678-6159
• Employees: 130
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.05 million
• Net Margins: -92.19%
• Pretax Margin: -92.19%
• Return on Equity: -325.86%
• Return on Assets: -56.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.07
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: $26.92 million
• Price / Sales: 7.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 32.36

Miscellaneous

• Outstanding Shares: 86,000,000
• Free Float: 70,719,000
• Market Cap: $194.79 million
• Optionable: Not Optionable
• Beta: 1.44